NCT03574584 - A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

July 27, 2019

Study Completion Date

July 27, 2019

Conditions

Metabolism and Nutrition DisordersOverweight or Obesity

Interventions

DRUG

NNC0165-1562

Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

DRUG

Semaglutide

Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.

DRUG

Placebo (NNC0165-1562)

Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.

Trial Locations (2)

68502

Novo Nordisk Investigational Site, Lincoln

85283

Novo Nordisk Investigational Site, Tempe